{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:05:32Z","timestamp":1788822332639,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.esmoop.2022.100588","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T21:16:08Z","timestamp":1663276568000},"page":"100588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-0953","authenticated-orcid":false,"given":"E.","family":"Aamdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Skovlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.D.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Straume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Herlofsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Amundsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dalhaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nyakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.T.","family":"Hagene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Holmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aamdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kaasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.K.","family":"Guren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Kyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmoop.2022.100588_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100588_bib2","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100588_bib4","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1002\/cncr.32824","article-title":"Determinants of quality of life in patients with incurable cancer","volume":"126","author":"Daly","year":"2020","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100588_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100588_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2011.11.011","article-title":"Health-related quality of life in patients with melanoma: overview of instruments and outcomes","volume":"30","author":"Cormier","year":"2012","journal-title":"Dermatol Clin"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100588_bib7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.ejca.2005.05.007","article-title":"Health related quality of life outcomes in cancer clinical trials","volume":"41","author":"Bottomley","year":"2005","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100588_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CMR.0b013e32835e5932","article-title":"What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire","volume":"23","author":"Winstanley","year":"2013","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100588_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1684\/ejd.2019.3523","article-title":"Comparison of quality of life between melanoma and non-melanoma skin cancer patients","volume":"29","author":"Sampogna","year":"2019","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100588_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00435223","article-title":"The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique","volume":"2","author":"Sigurdard\u00f3ttir","year":"1993","journal-title":"Qual Life Res"},{"issue":"suppl 6 suppl 6","key":"10.1016\/j.esmoop.2022.100588_bib11","doi-asserted-by":"crossref","first-page":"vi51","DOI":"10.1093\/annonc\/mdp255","article-title":"A\u00a0systematic review of health-related quality of life in cutaneous melanoma","volume":"20","author":"Cornish","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100588_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ijc.33768","article-title":"Ipilimumab in a real-world population: a prospective phase IV trial with long-term follow-up","volume":"150","author":"Aamdal","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100588_bib13","series-title":"Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100588_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100588_bib15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.1998.16.3.1188","article-title":"Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ\u00a0= C30 (+ 3)","volume":"16","author":"Hjermstad","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100588_bib16","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1002\/cam4.2940","article-title":"Cancer patients' experiences with immune checkpoint modulators: a qualitative study","volume":"9","author":"Ala-Leppilampi","year":"2020","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100588_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","article-title":"Integrating response shift into health-related quality of life research: a theoretical model","volume":"48","author":"Sprangers","year":"1999","journal-title":"Soc Sci Med"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100588_bib18","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/(SICI)1097-0258(19970615)16:11<1197::AID-SIM531>3.0.CO;2-9","article-title":"Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy","volume":"16","author":"Fairclough","year":"1997","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100588_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/0284186X.2020.1747636","article-title":"BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis","volume":"59","author":"Ny","year":"2020","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100588_bib20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ejca.2015.03.004","article-title":"Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma","volume":"51","author":"Schadendorf","year":"2015","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100588_bib21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100588_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2017.04.026","article-title":"Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status","volume":"81","author":"Thomsen","year":"2017","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100588_bib23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue \u2013 mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100588_bib24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.pain.2010.10.035","article-title":"Cancer pain and its relationship to systemic inflammation: an exploratory study","volume":"152","author":"Laird","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.esmoop.2022.100588_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7525-10-66","article-title":"Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment","volume":"10","author":"Revicki","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.esmoop.2022.100588_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100588_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1186\/s12885-021-08032-y","article-title":"Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study","volume":"21","author":"Dalle","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2022.100588_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2017.05.031","article-title":"Health-related quality of life results from the phase III CheckMate 067 study","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100588_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cncr.32554","article-title":"Quality-of-life assessment in French patients with metastatic melanoma in real life","volume":"126","author":"Kandel","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100588_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100588_bib31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/jdv.15487","article-title":"Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer","volume":"33","author":"Chernyshov","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"suppl_4","key":"10.1016\/j.esmoop.2022.100588_bib32","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100588_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","article-title":"Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls","volume":"60","author":"Boekhout","year":"2021","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100588_bib34","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/0959-8049(93)90115-V","article-title":"Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma","volume":"29A","author":"Coates","year":"1993","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100588_bib35","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/bjc.2016.107","article-title":"Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy","volume":"114","author":"Bowyer","year":"2016","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100588_bib36","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:00Z","timestamp":1761856140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2059702922002186"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100588","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100588"}}